临床前CDMO研发筛选相关化合物如有产品调研服务, 请致函联系我们
客户展示
临床前CDMO研发化合物筛选
9-amino-CPT (9-Aminocamptothecin)
中文名称: 9-氨基喜树碱
CAS号:91421-43-1
分子式: C20H17N3O4 分子量: 363.37
产品形式: Free base
研发状态: Unknown status
研发用途: Traditional Chinese Medicine; Dyslipidemias; Syndrome
研究机构: Dongzhimen Hospital Beijing
研发日期: April 21 2021
研发阶段: --
9-amino-CPT (9-Aminocamptothecin, 9-AC, Aminocamptothecin, 9-amino-20(S)-camptothecin) is a Topoisomerase I inhibitor with potent anticancer activities. 9-amino-CPT (9-Aminocamptothecin) is an active, water-insoluble derivative of camptothecin.
Rubitecan
中文名称: 9-硝基喜树碱
CAS号:91421-42-0
分子式: C20H15N3O6 分子量: 393.35
产品形式: Free Base
研发状态: Completed
研发用途: Influenza
研究机构: National Institute of Allergy and Infectious Diseases (NIAID)
研发日期: January 8 2019
研发阶段: Phase 1
Rubitecan (9-NC, 9-Nitro-camptothecin, Partaject Orathecin, Partaject rubitecan, RFS 2000) is a topoisomerase I inhibitor extracted from the bark and leaves of the Camptotheca acuminata tree, which is native to China. Rubitecan is an oral camptothecin with antitumour activity.
Ropinirole HCl
中文名称:盐酸罗匹尼罗
CAS号:91374-20-8
分子式: C16H24N2O.HCl 分子量: 296.84
产品形式: HCl
研发状态: Terminated
研发用途: Restless Legs Syndrome; End Stage Renal Disease
研究机构: University of Alberta
研发日期: February 19 2019
研发阶段: Phase 2
Ropinirole (SKF-101468A) a selective dopamine D2 receptors agonist with Ki of 29 nM.
Onalespib (AT13387)
中文名称:奥那司匹
CAS号:912999-49-6
分子式: C24H31N3O3 分子量: 409.52
产品形式: free base
研发状态: Completed
研发用途: Metastatic High Grade Fallopian Tube Serous Adenocarcinoma; Metastatic Malignant Solid Neoplasm; Metastatic Primary Peritoneal Serous Adenocarcinoma; Metastatic Triple-Negative Breast Carcinoma; Platinum-Resistant Fallopian Tube Carcinoma; Platinum-Resistant Ovarian Carcinoma; Platinum-Resistant Primary Peritoneal Carcinoma; Recurrent Breast Carcinoma; Recurrent High Grade Fallopian Tube Serous Adenocarcinoma; Recurrent High Grade Ovarian Serous Adenocarcinoma; Recurrent Primary Peritoneal High Grade Serous Adenocarcinoma; Recurrent Triple-Negative Breast Carcinoma; Refractory Fallopian Tube Serous Adenocarcinoma; Refractory Ovarian Serous Adenocarcinoma; Refractory Primary Peritoneal Serous Adenocarcinoma; Refractory Triple-Negative Breast Carcinoma; Unresectable High Grade Fallopian Tube Serous Adenocarcinoma; Unresectable Malignant Solid Neoplasm; Unresectable Primary Peritoneal Serous Adenocarcinoma
研究机构: National Cancer Institute (NCI)
研发日期: May 19 2017
研发阶段: Phase 1
Onalespib (AT13387) is a selective potent Hsp90 inhibitor with IC50 of 18 nM in A375 cells, displays a long duration of anti-tumor activity. Phase 2.
Veliparib (ABT-888)
中文名称:维利帕尼
CAS号:912444-00-9
分子式: C13H16N4O 分子量: 244.29
产品形式: free base
研发状态: Withdrawn
研发用途: Cancer
研究机构: University Medical Center Groningen; AbbVie; Dutch Cancer Society
研发日期: Nov-19
研发阶段: Phase 2
Veliparib (ABT-888, NSC 737664) is a potent inhibitor of PARP1 and PARP2 with Ki of 5.2 nM and 2.9 nM in cell-free assays, respectively. It is inactive to SIRT2. Veliparib increases autophagy and apoptosis. Phase 3.
Gemigliptin
中文名称:吉格列汀
CAS号:911637-19-9
分子式: C18H19F8N5O2 分子量: 489.36
产品形式: Free Base
研发状态: Unknown status
研发用途: Diabetes Mellitus Type 2; Dyslipidemias
研究机构: LG Chem
研发日期: March 21 2019
研发阶段: Phase 1
Gemigliptin (Zemiglo, LC15-0444) is a potent, selective and long-acting dipeptidyl peptidase 4 (DPP 4) inhibitor with a Ki of 7.25 nM. Gemigliptin shows at least >23,000-fold selectivity for DPP-4 over various proteases and peptidases, including DPP-8, DPP-9, and fibroblast activation protein (FAP)-α.
我们的宗旨: 净化, 简洁, 高效Purifying, concise, efficient !我们的口号: 减少中间商赚差价!
即日起可免费注册成为会员, 建立企业产品库, 免费上传产品目录, 企业介绍等. 让你的产品直接呈现给客户.
试运营阶段,所有广告业务5折优惠
分类广告投放
依据化学成分的不同, 针对不同的企业和产品, 我们提供分类产品广告投放.客户展示
优秀企业推荐
